Immunohistochemical analysis of ezrin-radixin-moesin-binding phosphoprotein 50 in prostatic adenocarcinoma

BMC Urology

Volumn 11, Issue , 2011, Pages

  Bartholow, Tanner L ^a   Becich, Michael J ^a   Chandran, Uma R ^a   Parwani, Anil V ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; EZRIN; EZRIN RADIXIN MOESIN BINDING PHOSPHOPROTEIN 50; MOESIN; PHOSPHOPROTEIN; RADIXIN; UNCLASSIFIED DRUG; SODIUM HYDROGEN EXCHANGER REGULATORY FACTOR; SODIUM PROTON EXCHANGE PROTEIN; SODIUM-HYDROGEN EXCHANGER REGULATORY FACTOR; TUMOR MARKER; TUMOR PROTEIN;

ADULT; AGED; ARTICLE; CANCER GRADING; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTATIC PROSTATIC ADENOCARCINOMA; PRIMARY PROSTATIC ADENOCARCINOMA; PROSTATE ADENOCARCINOMA; PROSTATE HYPERTROPHY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN BINDING; PROTEIN EXPRESSION; STAINING; TISSUE MICROARRAY; ADENOCARCINOMA; METABOLISM; MIDDLE AGED; PROSTATE TUMOR; TISSUE DISTRIBUTION;

ADENOCARCINOMA; AGED; HUMANS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PHOSPHOPROTEINS; PROSTATIC NEOPLASMS; SODIUM-HYDROGEN ANTIPORTER; TISSUE DISTRIBUTION; TUMOR MARKERS, BIOLOGICAL;

EID: 79958259035     PISSN: None     EISSN: 14712490     Source Type: Journal    
DOI: 10.1186/1471-2490-11-12     Document Type: Article

References (34)

1. Cancer statistics, 2010. A Jemal R Siegel J Xu E Ward, CA Cancer J Clin 2010 60 277 300 10.3322/caac.20073 20610543
2. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. R Etzioni DF Penson JM Legler D di Tommaso R Boer PH Gann EJ Feuer, J Natl Cancer Inst 2002 94 13 981 990 12096083 (Pubitemid 34814727)
3. Differences in gene expression in prostate cancer, normal appearing prostate tissue adjacent to cancer and prostate tissue from cancer free organ donors. UR Chandran R Dhir C Ma G Michalopoulos M Becich J Gilbertson, BMC Cancer 2005 5 45 10.1186/1471-2407-5-45 15892885
4. NHERF1/EBP50 in Breast Cancer. A Bellizzi A Malfettone RA Cardone A Mangia, Clinical Perspectives Breast Care (Basel) 2010 5 2 86 90
5. Roles of NHERF1/EBP50 in cancer. MM Georgescu FC Morales JR Molina Y Hayashi, Curr Mol Med 2008 8 6 459 468 10.2174/156652408785748031 18781953
6. Ezrin-radixin-moesin (ERM)-binding phosphoprotein 50 organizes ERM proteins at the apical membrane of polarized epithelia. FC Morales Y Takahashi EL Kreimann MM Georgescu, Proc Natl Acad Sci USA 2004 101 51 17705 17710 10.1073/pnas.0407974101 15591354 (Pubitemid 40051950)
7. Loss of PTEN binding adapter protein NHERF1 from plasma membrane in glioblastoma contributes to PTEN inactivation. JR Molina FC Morales Y Hayashi KD Aldape MM Georgescu, Cancer Res 2010 70 17 6697 6703 10.1158/0008-5472.CAN-10- 1271 20736378
8. Cortical stabilization of beta-catenin contributes to NHERF1/EBP50 tumor suppressor function. EL Kreimann FC Morales J de Orbeta-Cruz Y Takahashi H Adams TJ Liu PD McCrea MM Georgescu, Oncogene 2007 26 36 5290 5299 10.1038/sj.onc.1210336 17325659 (Pubitemid 47237631)
9. NHERF (Na+/H+ exchanger regulatory factor) gene mutations in human breast cancer. JL Dai L Wang AA Sahin LD Broemeling M Schutte Y Pan, Oncogene 2004 23 53 8681 8687 10.1038/sj.onc.1207962 15467753 (Pubitemid 39576475)
10. Suppression of breast cancer cell growth by Na+/H+ exchanger regulatory factor 1 (NHERF1). Y Pan L Wang JL Dai, Breast Cancer Res 2006 8 6 63 10.1186/bcr1616 17078868
11. EBP50 exerts tumor suppressor activity by promoting cell apoptosis and retarding extracellular signal-regulated kinase activity. JF Zheng LC Sun H Liu Y Huang Y Li J He, Amino Acids 2010 38 4 1261 1268 10.1007/s00726-009-0437-2 20012548
12. EBP50, a beta-catenin-associating protein, enhances Wnt signaling and is over-expressed in hepatocellular carcinoma. T Shibata M Chuma A Kokubu M Sakamoto S Hirohashi, Hepatology 2003 38 1 178 186 10.1053/jhep.2003.50270 12830000 (Pubitemid 36775809)
13. NHERF1/EBP50 is a new marker in colorectal cancer. Y Hayashi JR Molina SR Hamilton MM Georgescu, Neoplasia 2010 12 12 1013 1022 21170265
14. Expression and clinicopathological significance of oestrogen-responsive ezrin-radixin-moesin-binding phosphoprotein 50 in breast cancer. J Song J Bai W Yang EW Gabrielson DW Chan Z Zhang, Histopathology 2007 51 1 40 53 10.1111/j.1365-2559.2007.02730.x 17593079 (Pubitemid 46976376)
15. Practical aspects of planning, building, and interpreting tissue microarrays: the Cooperative Prostate Cancer Tissue Resource experience. A Kajdacsy-Balla JM Geynisman V Macias S Setty NM Nanaji JJ Berman K Dobbin J Melamed X Kong M Bosland J Orenstein J Bayarl M Becich R Dhir MW Datta, J Mol Histol 2007 38 2 113 121 10.1007/s10735-006-9054-5 17318343 (Pubitemid 46659332)
16. Using image analysis as a tool for assessment of prognostic and predictive biomarkers for breast cancer: How reliable is it? MC Lloyd P Allam-Nandyala CN Purohit N Burke D Coppola MM Bui, J Pathol Inform 2010 1 29 10.4103/2153-3539.74186 21221174
17. Assessment of automated image analysis of breast cancer tissue microarrays for epidemiologic studies. KL Bolton M Garcia-Closas RM Pfeiffer MA Duggan WJ Howat SM Hewitt XR Yang R Cornelison SL Anzick P Meltzer S Davis P Lenz JD Figueroa PD Pharoah ME Sherman, Cancer Epidemiol Biomarkers Prev 2010 19 4 992 999 10.1158/1055-9965.EPI-09-1023 20332278
18. ERM proteins: from cellular architecture to cell signaling. S Louvet-Vallee, Biol Cell 2000 92 5 305 316 10.1016/S0248-4900(00)01078-9 11071040
19. Immunohistochemical staining of radixin and moesin in prostatic adenocarcinoma. TL Bartholow UR Chandran MJ Becich AV Parwani, BMC Clin Pathol 2011 11 1 10.1186/1472-6890-11-1 21235778
20. Phases of biomarker development for early detection of cancer. MS Pepe R Etzioni Z Feng JD Potter ML Thompson M Thornquist M Winget Y Yasui, J Natl Cancer Inst 2001 93 14 1054 1061 10.1093/jnci/93.14.1054 11459866 (Pubitemid 32717537)
21. The NHERF1 PDZ2 domain regulates PKA-RhoA-p38-mediated NHE1 activation and invasion in breast tumor cells. RA Cardone A Bellizzi G Busco EJ Weinman ME Dell'Aquila V Casavola A Azzariti A Mangia A Paradiso SJ Reshkin, Mol Biol Cell 2007 18 5 1768 1780 10.1091/mbc.E06-07-0617 17332506 (Pubitemid 46717558)
22. Contact-dependent inhibition of EGFR signaling by Nf2/Merlin. M Curto BK Cole D Lallemand CH Liu AI McClatchey, J Cell Biol 2007 177 5 893 903 10.1083/jcb.200703010 17548515 (Pubitemid 46873094)
23. A NHERF binding site links the betaPDGFR to the cytoskeleton and regulates cell spreading and migration. MF James RL Beauchamp N Manchanda A Kazlauskas V Ramesh, J Cell Sci 2004 117 Pt 14 2951 2961 15161943 (Pubitemid 39117670)
24. Platelet-derived growth factor receptor association with Na(+)/H(+) exchanger regulatory factor potentiates receptor activity. S Maudsley AM Zamah N Rahman JT Blitzer LM Luttrell RJ Lefkowitz RA Hall, Mol Cell Biol 2000 20 22 8352 8363 10.1128/MCB.20.22.8352-8363.2000 11046132
25. Biological role of NHERF1 protein expression in breast cancer. A Mangia A Chiriatti A Bellizzi A Malfettone B Stea FA Zito SJ Reshkin G Simone A Paradiso, Histopathology 2009 55 5 600 608 10.1111/j.1365-2559.2009.03424.x 19912366
26. Molecular and functional genetics of hepatocellular carcinoma. JW Yam CM Wong IO Ng, Front Biosci (Schol Ed) 2010 2 117 134
27. Roles and regulation of Wnt signaling and beta-catenin in prostate cancer. M Verras Z Sun, Cancer Lett 2006 237 1 22 32 10.1016/j.canlet.2005.06. 004 16023783
28. Beta-catenin affects androgen receptor transcriptional activity and ligand specificity. CI Truica S Byers EP Gelmann, Cancer Res 2000 60 17 4709 4713 10987273
29. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. PA Steck MA Pershouse SA Jasser WK Yung H Lin AH Ligon LA Langford ML Baumgard T Hattier T Davis C Fyre R Hu B Swedlund OH Teng SV Tavtigian, Nat Genet 1997 15 4 356 362 10.1038/ng0497-356 9090379 (Pubitemid 27147102)
30. Phosphatidylinositol 3-kinase/Akt stimulates androgen pathway through GSK3beta inhibition and nuclear beta-catenin accumulation. M Sharma WW Chuang Z Sun, J Biol Chem 2002 277 34 30935 30941 10.1074/jbc.M201919200 12063252 (Pubitemid 34970795)
31. NHERF1/EBP50 head-to-tail intramolecular interaction masks association with PDZ domain ligands. FC Morales Y Takahashi S Momin H Adams X Chen MM Georgescu, Mol Cell Biol 2007 27 7 2527 2537 10.1128/MCB.01372-06 17242191 (Pubitemid 46581344)
32. Ezrin is essential for epithelial organization and villus morphogenesis in the developing intestine. I Saotome M Curto AI McClatchey, Dev Cell 2004 6 6 855 864 10.1016/j.devcel.2004.05.007 15177033 (Pubitemid 38745419)
33. Prognostic significance of E-cadherin and ezrin immunohistochemical expression in prostate cancer. J Musial S Sporny A Nowicki, Pol J Pathol 2007 58 4 235 243 18459457 (Pubitemid 351428300)
34. Clinical significance of cellular distribution of moesin in patients with oral squamous cell carcinoma. H Kobayashi J Sagara H Kurita M Morifuji M Ohishi K Kurashina S Taniguchi, Clin Cancer Res 2004 10 2 572 580 10.1158/1078-0432. CCR-1323-03 14760079 (Pubitemid 38173996)